ABPI’s Disclosure UK shows the pharmaceutical industry continues to invest in UK R&D:
“We are now fewer than nine months away from the day the UK leaves the EU and as it stands we still do not have a deal on the future relationship or any certainty on the conditions our companies are expected to operate under come 29 March 2019...
A survey into Brexit planning by pharmaceutical companies has been published by the European Medicines Agency (EMA).
Simon Stevens appeared on the Andrew Marr Show on Sunday 1 July and was asked about preparations for Brexit and contingency planning for a no-deal scenario to ensure the continued supply of medicines to the UK.
Today sees the launch of a consultation on proposals to change the 2016 ABPI Code of Practice for the pharmaceutical industry.
The ABPI today welcomes the publication of technical notices issued by the Government and the letter from the Department of Health and Social Care on medicines supply contingency planning. This gives guidance to pharmaceutical companies as they prepare for Brexit.
Health experts in the UK have identified what they believe to be the ten most important and impactful medicines and vaccines introduced in to the NHS in the past 70 years.
The MHRA has published technical guidance on what a Brexit implementation period means for the life sciences sector, once finalised as part of the Withdrawal Agreement.
Yesterday, the European Medicines Agency (EMA) announced that it will further temporarily scale back and suspend activities in preparation for Brexit. The EMA said that it expects a staff loss of about 30%.